1. Expert Insights in Diagnosis and Management of Common Drug-Induced Movement Disorders

3. Overview of TD

4. TD Burden, Prevalence, Incidence

5. TD Prevalence and Incidence Rates

6. TD Burden and Impact on QoL

7. Impact of TD on Highly Functional Patients

8. TD Risk Factors

9. Differential Diagnosis

10. Is It Tardive Dyskinesia or Drug-Induced Parkinsonism?

11. Schooler-Kane Criteria Commonly Used Criteria Based on AIMS Score

12. AIMS Useful for Screening and Following Symptoms

13. AIMS Useful for Screening and Following Symptoms (cont)

14. Interprofessional Team Approach

15. TD Prevention and Treatment

16. VMAT2 Inhibitors

17. ARM-TD and AIM-TD Study Designs

18. ARM-TD and AIM-TD Results

19. RIM-TD

20. KINECT 3 and KINECT 4 Study Designs

21. KINECT 3 and KINECT 4 Results

22. Real‐World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Agents (RE-KINECT)

23. VMAT2 Inhibitors and Psychiatric AEs

24. Comparison of Deutetrabenazine and Valbenazine

25. Comparison of Deutetrabenazine and Valbenazine (cont)

26. Considerations for Initiating Treatment The Patient's Perspective

27. AAN Recommendations for Treatment of TD

28. Concluding Remarks

29. Concluding Remarks (cont)

30. Abbreviations

31. Abbreviations (cont)